7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Arterial thrombosis; Catheter thrombosis; Venous thrombosis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms EINSTEIN; Einstein Jr
- Sponsors Bayer; Bayer HealthCare
- 04 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
- 04 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 04 Jan 2017 Status changed from suspended to recruiting.